These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 22860709)

  • 21. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
    Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
    Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
    Taguchi T
    Gan To Kagaku Ryoho; 2002 Feb; 29 Suppl 1():76-80. PubMed ID: 11890118
    [No Abstract]   [Full Text] [Related]  

  • 23. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
    Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
    Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
    Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
    Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. S-1: a promising new oral fluoropyrimidine derivative.
    Saif MW; Syrigos KN; Katirtzoglou NA
    Expert Opin Investig Drugs; 2009 Mar; 18(3):335-48. PubMed ID: 19243284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Controversial issues in chemotherapy for inoperable gastric cancer].
    Koizumi W; Tanabe S; Higuchi K; Sasaki T; Nakayama N; Nagaba S; Kitamura T; Azuma M; Saigenji K
    Gan To Kagaku Ryoho; 2003 Sep; 30(9):1249-55. PubMed ID: 14518402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systemic analysis of S-1 regimens for treatment of patients with colon cancer.
    Zhang E; Cao W; Cheng C; Huo BL; Wang YH
    Asian Pac J Cancer Prev; 2014; 15(5):2191-4. PubMed ID: 24716955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
    Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
    Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
    Prescrire Int; 2013 May; 22(138):122. PubMed ID: 23819172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer.
    Kinoshita T; Nashimoto A; Yamamura Y; Okamura T; Sasako M; Sakamoto J; Kojima H; Hiratsuka M; Arai K; Sairenji M; Fukushima N; Kimura H; Nakajima T
    Gastric Cancer; 2004; 7(2):104-9. PubMed ID: 15224197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
    Ohtsu A; Shimada Y; Shirao K; Boku N; Hyodo I; Saito H; Yamamichi N; Miyata Y; Ikeda N; Yamamoto S; Fukuda H; Yoshida S;
    J Clin Oncol; 2003 Jan; 21(1):54-9. PubMed ID: 12506170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
    Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
    Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
    Higashi D; Egawa Y; Hirano Y; Hirano K; Miyake T; Takahashi H; Uwatoko S; Abe S; Yamamoto S; Mikami K; Futami K; Maekawa T; Inoue R; Miyazaki M
    Anticancer Res; 2014 Aug; 34(8):4595-9. PubMed ID: 25075105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
    Pozzo C; Barone C
    Oncologist; 2008 Jul; 13(7):794-806. PubMed ID: 18614586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Other fluorinated pyrimidines in the treatment of solid tumors.
    Saad ED; Hoff PM
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 2):65-8. PubMed ID: 11219980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. S-1 in gastric cancer: a comprehensive review.
    Maehara Y
    Gastric Cancer; 2003; 6 Suppl 1():2-8. PubMed ID: 12775012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of S-1 in the treatment of gastric cancer.
    Kubota T
    Br J Cancer; 2008 Apr; 98(8):1301-4. PubMed ID: 18362933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2).
    Nakata B; Tsuji A; Mitachi Y; Taenaka N; Kamano T; Oikawa K; Onoda N; Kambe M; Takahashi M; Shirasaka T; Morita S; Sakamoto J; Tanaka Y; Saji S; Hirakawa K
    Oncology; 2010; 79(5-6):337-42. PubMed ID: 21430401
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
    Shirasaka T; Aiba K; Araki H; Suzuki M; Terashima M; Mikami Y
    Gan To Kagaku Ryoho; 1999 Mar; 26(4):456-66. PubMed ID: 10097742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.